IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced appetite.

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

GLP-1 agonists have gained recent widespread attention, reshaping treatment approaches for several diseases, including diabetes and cardiovascular disease. 2 In the treatment of type 2 diabetes, ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...